Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b ...

Moderna and Merck said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...

Moderna and Merck shared five-year study data showing their combined cancer treatment cut the risk of melanoma coming back or ...

Moderna shares surge 30% in 2026 on raised revenue forecast and cost cuts. Technical breakout suggests continued momentum ...

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...

The overall sentiment of these big-money traders is split between 54% bullish and 36%, bearish. Out of all of the special options we uncovered, 11 are puts, for a total amount of $951,480, and 11 are ...

Stéphane Bancel, CEO of vaccine maker Moderna, addressed shareholders in a letter that dissected the events of 2025 while ...

Jan 20 () - Moderna ​and Merck ‌said on ‌Tuesday their experimental vaccine for ⁠a ‌serious type of ‍skin cancer, used in ...